The content on this site is intended for healthcare professionals only
Dr Van De Donk talks to ecancertv at ICMM 2016 about the results of phase II and III trials looking at drug combinations involving daratumumab for the treatment of myeloma patients.
He says that triple drug regimens will probably be the future but that biomarkers are still needed to see which patients will respond.
For more on this, see the interview with Dr Plesner
ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Multiple myeloma in a resource constrained setting
